Novo Nordisk(NVO) GlobeNewswire News Room·2025-01-29 16:13Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Novo Nordisk A/S due to allegations of violations of federal securities laws related to misleading statements about the REDEFINE-1 trial protocol and its results [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Novo Nordisk to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against Novo Nordisk, with a deadline of March 25, 2025, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Trial Protocol Allegations - The complaint alleges that Novo Nordisk and its executives made false and misleading statements regarding the REDEFINE-1 trial, particularly about the "flexible protocol" that allowed patients to modify their dosing [4]. - On December 20, 2024, Novo announced that the average weight loss achieved in the REDEFINE-1 trial was only 22.7% after 68 weeks, attributing this to the previously undisclosed flexible nature of the trial protocol [4]. Group 3: Market Reaction - Following the announcement of the trial results, Novo Nordisk's stock price fell from 85.00 per share on December 20, 2024, marking a decline of approximately 17.83% in one day [5].